Cargando…

Patients Dispensed Medications with Actionable Pharmacogenomic Biomarkers: Rates and Characteristics

PURPOSE. Pharmacogenomic biomarkers are increasingly listed on medication labels and authoritative guidelines but pharmacogenomic-guided prescribing is not yet common. Our objective was to assess the potential for incorporating knowledge of patients’ genomic characteristics into prescribing practice...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Dianbo, Olson, Karen L., Manzi, Shannon F., Mandl, Kenneth D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067543/ https://www.ncbi.nlm.nih.gov/pubmed/33420348 http://dx.doi.org/10.1038/s41436-020-01044-2

Ejemplares similares

Temporal Patterns of Medications Dispensed to Children and Adolescents in a National Insured Population
por: Olson, Karen L., et al.
Publicado: (2012)

Integration of a standardized pharmacogenomic platform for clinical decision support at Boston Children's Hospital
por: Brownstein, Catherine, et al.
Publicado: (2012)

Pharmacogenomically actionable medications in a safety net health care system
por: Carpenter, Janet S, et al.
Publicado: (2016)

Pharmacogenomic Biomarkers
por: Kirkwood, Sandra C., et al.
Publicado: (2002)

Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B
por: Potts, Malia B., et al.
Publicado: (2015)

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics
por: Mizzi, Clint, et al.
Publicado: (2016)

Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics
por: Mizzi, Clint, et al.
Publicado: (2017)

Metformin Pharmacogenomics: Biomarkers to Mechanisms
por: Wang, Liewei, et al.
Publicado: (2014)

Pharmacogenomic Biomarkers and Their Applications in Psychiatry
por: Kam, Heejin, et al.
Publicado: (2020)

Patient-Level Exposure to Actionable Pharmacogenomic Medications in a Nationally Representative Insurance Claims Database
por: Bianchini, Monica L., et al.
Publicado: (2023)

Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
por: Genovesi, Laura A., et al.
Publicado: (2021)

The role of environmental factors on transmission rates of the COVID-19 outbreak: an initial assessment in two spatial scales
por: Poirier, Canelle, et al.
Publicado: (2020)

Personalizing Personalized Medicine: The Confluence of Pharmacogenomics, a Person’s Medication Experience and Ethics
por: Stratton, Timothy P., et al.
Publicado: (2023)

Editorial: Pharmacogenomics and ethnicity: Prevalence and clinical significance of pharmacogenomic biomarkers in indigenous and other populations
por: Patrinos, George P., et al.
Publicado: (2023)

Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use
por: Chin, Lauren, et al.
Publicado: (2017)

Should Medical Practitioners Dispense?: III. Prescriber and Dispenser
Publicado: (1910)

MOMC-5. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
por: Genovesi, Laura, et al.
Publicado: (2021)

Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update
por: Ab Mutalib, Nurul-Syakima, et al.
Publicado: (2017)

Pharmacogenomics Biomarkers of Soft Tissue Sarcoma Therapies
por: Caruso, Chiara, et al.
Publicado: (2020)

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy
por: Al-Mahayri, Zeina N., et al.
Publicado: (2020)

Medication Abortion With Pharmacist Dispensing of Mifepristone
por: Grossman, Daniel, et al.
Publicado: (2021)

Medication reconciliation to support pharmacogenomics implementation
por: Mosley, Scott A., et al.
Publicado: (2022)

Adverse drug event rates in pediatric pulmonary hypertension: a comparison of real-world data sources
por: Geva, Alon, et al.
Publicado: (2019)

Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence
por: Schuh, Michael J., et al.
Publicado: (2020)

Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing
por: Van Driest, Sara L., et al.
Publicado: (2013)

Prevalence and Characteristics of Interventional Trials Conducted Exclusively in Elderly Persons: A Cross-Sectional Analysis of Registered Clinical Trials
por: Bourgeois, Florence T., et al.
Publicado: (2016)

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
por: Arbitrio, Mariamena, et al.
Publicado: (2020)

Pharmacogenomics
Publicado: (2008)

Pharmacogenomics
Publicado: (2008)

Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis
por: Annane, Djillali, et al.
Publicado: (2018)

Realities of Pharmacogenomic and Minimizing Misconceptions and Medication Misadventures
por: Duong, Benjamin
Publicado: (2021)

Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting
por: Mostafa, Sam, et al.
Publicado: (2021)

An assessment of patient perspectives on pharmacogenomics educational materials
por: Asiedu, Gladys B, et al.
Publicado: (2020)

Pharmacogenomics cascade testing (PhaCT): a novel approach for preemptive pharmacogenomics testing to optimize medication therapy
por: Roosan, Don, et al.
Publicado: (2020)

Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders
por: Cacabelos, Ramón
Publicado: (2009)

Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy
por: Correia, Catarina, et al.
Publicado: (2022)

Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers
por: Li, Liang, et al.
Publicado: (2009)

Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)
por: Just, Katja Susanne, et al.
Publicado: (2017)

Pharmacogenomic Approaches for Automated Medication Risk Assessment in People with Polypharmacy
por: Liu, Jiazhen, et al.
Publicado: (2018)

Medication adherence and clinical outcomes in dispensing and non-dispensing practices: a cross-sectional analysis
por: Gomez-Cano, Mayam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t2dgh07jl8cj0capo6kcdrshpu